youtube_live
Q3 2026 earnings • in 4 days
See detailschevron_right
ALNY:NASDAQ
Alnylam Pharmaceuticals, Inc.
$224.03
arrow_downward
-1.43%(-3.25) 1D
$224.03
0.00% (0.00)
bedtimeAfter hours
Closed: Oct 23, 4:00:01 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ALNY...
Open
$227.28
High
$229.39
Low
$222.00
Mkt. cap
29.98B
Avg. vol.
1.33M
Volume
1.06M
P/E ratio
38.13
52-wk high
$485.36
52-wk low
$197.81
EPS
$5.88
Beta
0.28
Shares outstanding
133.81M
No. of employees
2K
Open
$227.28
High
$229.39
Low
$222.00
Mkt. cap
29.98B
Avg. vol.
1.33M
Volume
1.06M
P/E ratio
38.13
52-wk high
$485.36
52-wk low
$197.81
EPS
$5.88
Beta
0.28
Shares outstanding
133.81M
No. of employees
2K
News stories
From web sources and news partners
Investing.com
·
1 day ago
Raymond James reiterates Alnylam stock Strong Buy on positive trial data
BioSpace
·
2 days ago
Alnylam plans pivotal trial as Huntington’s drug notches ‘best-in-class knockdown’
Yahoo Finance
·
3 days ago
Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Profile
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list. Wikipedia
About Alnylam Pharmaceuticals, Inc.
CEOYvonne Greenstreet
Employees2.5K
FoundedJun 14, 2002
Headquarters-
SectorBiotechnology
Websitealnylam.com